Citations

Clear

61 citation(s) found for "Shepard, M J".

Development of an Automated Triage System for Longstanding Dizzy Patients Using Artificial Intelligence
Macielak, Robert J. , Eggers, Scott D.Z. , Driscoll, Colin L. W., Shepard, Neil T., Albertson, Sabrina M., McCaslin, Devin L. , Macielak, Robert James , Romero‐Brufau, Santiago , Staab, Jeffrey P. , Totten, Douglas J. , Pasupathy, Kalyan S.

Mayo Clinic

OTO Open | September 27, 2024 | Volume: 8 | Issue: 3 | Pages: No page available

10.1002/oto2.70006 | PMID 39345332 Get It

AbstractObjectiveTo report the first steps of a project to automate and optimize scheduling of multidisciplinary consultations for patients with longstanding dizziness utilizing artificial intelligence.Study DesignRetrospective case review.SettingQuaternary referral center.MethodsA previsit self‐report questionnaire was developed to query patients about their complaints of longstanding dizziness. We convened an expert panel of clinicians to review diagnostic outcomes for 98 patients and used a consensus approach to retrospectively determine what would have been the ideal appointments based on the patient's final diagnoses. These results were then compared retrospectively to the actual patient schedules. From these data, a machine learning algorithm was trained and validated to automate the triage process.ResultsCompared with the ideal itineraries determined retrospectively with our expert panel, visits scheduled by the triage clinicians showed a mean concordance of 70%, and our machine learning algorithm triage showed a mean concordance of 79%.ConclusionManual triage by clinicians for dizzy patients is a time‐consuming and costly process. The formulated first‐generation automated triage algorithm achieved similar results to clinicians when triaging dizzy patients using data obtained directly from an online previsit questionnaire.
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
Schuetze, Scott M. , Heise, Rachel S. , Ganjoo, Kristen N. , Davis, Elizabeth J. , George, Suzanne , Burgess, Melissa , Choy, Edwin , Shepard, Dale R. , Tinoco, Gabriel , Kelly, Ciara M. , Attia, Steven , Deshpande, Hari A. , Riedel, Richard F. , Kozlowski, Erin , Astbury, Caroline , Ballman, Karla V. , Schuetze, Scott M , Heise, Rachel , Ganjoo, Kristen N , Davis, Elizabeth J , George, Suzanne , Burgess, Melissa A , Choy, Edwin , Shepard, Dale R , Tinoco, Gabriel , Hirbe, Angela C , Kelly, Ciara M , Attia, Steven , Deshpande, Hari A , Schwartz, Gary K , Siontis, Brittany L , Riedel, Richard F , von Mehren, Margaret , Kozlowski, Erin , Chen, Helen X , Astbury, Caroline , Rubin, Brian P. , Ballman, Karla , Hirbe, Angela C. , Schwartz, Gary K. , Siontis, Brittany L. , Mehren, Margaret von

Mayo Clinic

Clinical Cancer Research | March 6, 2024 | Volume: 30 | Issue: 20 | Pages: 4584-4592

10.1158/1078-0432.ccr-23-3817 | PMID 38446990 Get It

Abstract Purpose: Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer with pathogenic TAZ–CAMTA1 (calmodulinbinding transcription activator 1) operating as an oncogenic driver through activation of the MAPK pathway. Trametinib is an inhibitor of MEK, a critical kinase in the MAPK pathway. We sought to evaluate the effect of trametinib in patients with EHE. Patients and Methods: A phase 2 trial of trametinib was conducted in patients with locally advanced or metastatic EHE. Eligibility requirements included evidence of tumor progression or presence of EHE-related pain requiring opiates for management before enrollment. The primary endpoint was objective response rate (ORR) as per RECIST1.1 in cases with TAZ– CAMTA1 confirmed by fusion-FISH. Secondary objectives were to estimate ORR for all patients, median progression-free survival (PFS), 2-year overall survival (OS) rate, patient safety, and change in patient-reported global health and pain scores per PROMIS questionnaires. Results: 44 patients enrolled and 42 started trametinib. TAZ– CAMTA1 was detected in 27 tumor samples. TheORRwas 3.7%[95% confidence interval (CI), 0.094–19.0], median PFS was 10.4 months (95%CI, 7.1–NA), and 2-year OS rate was 33.3%(95%CI, 19.1–58.2) in the target population. Median pain intensity and interference scores improved significantly after 4 weeks of trametinib in patients using opiates. Common adverse events related to trametinib were rash, fatigue, nausea/vomiting, diarrhea/constipation, alopecia, and edema; one grade 5 ARDS/pneumonitis was related to trametinib. Conclusions: Trametinib was associated with reduction in EHE-related pain and median PFS of more than 6 months, providing palliative benefit in patients with advanced EHE, but the trial did not meet the ORR goal. See related commentary by Van Tine and Haarberg, p. 4552
The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study
Warnick, Ronald E. , Adam, Elizabeth , Iorio‐Morin, Christian , Leduc, William, Hamel, Andréanne, Johnson, Sarah E. , Bydon, Mohamad , Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Waite, Kaitlin, Jose, Shalini, Peker, Selçuk , Samanci, Mustafa Yavuz, Tek, Ece, Pikis, Stylianos , Sheehan, Jason P. , Kumar, Narendra , Bernstein, Kenneth , Ahorukomeye, Peter , Kshettry, Varun R. , Hernández, Wenceslao, Urgošík, Dušan, Lee, John Y. K., Patel, Samir , Kusyk, Dorian , Shepard, Matthew J., Samancı, Yavuz , Paddick, Ian , Mathieu, David , Mantziaris, Georgios , Tripathi, Manjul , Alzate, Juan Diego , Speckter, Herwin , Liščák, Roman , Yang, Andrew I. , Kondziolka, Douglas

Mayo Clinic

Journal of Neurosurgery | February 17, 2024 | Volume: 141 | Issue: 2 | Pages: 461-473

10.3171/2023.12.jns231569 | PMID 38364220 Get It

OBJECTIVE Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure. METHODS This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value. RESULTS The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5–95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6–156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I–IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness. CONCLUSIONS BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.
RadioGraphics Update: The 10 Pillars of Lung Cancer Screening—Rationale and Logistics of a Lung Cancer Screening Program
Adams, Scott , Flores, Efrén J. , Sharma, Amita , Lennes, Inga T. , Shepard, Jo-Anne O. , Fintelmann, Florian J. , Adams, Scott J , Sharma, Amita , Shepard, Jo-Anne O , Fintelmann, Florian J , Flores, Efren J , Little, Brent P.

Mayo Clinic

RadioGraphics | February 8, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1148/rg.230057 | PMID 38329900 Get It

Co-Morbid Obstructive Sleep Apnea and Interictal Quality of Life Determinants in Refractory Epilepsy: A Pilot Study (P03.129)
Enke, Ashley, Shepard, Paul W., Dresow, Max, Dueffert, Lucas G., Louis, Erik K. St.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p03.129 Get It

Local control and survival after stereotactic radiosurgery for colorectal cancer brain metastases: an international multicenter analysis
Singh, Raj , Legarreta, Aimé Parra , Bowden, Greg , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Eldin, Reem Emad, Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Hess, Judith, Templeton, Kelsey, Zhang, Xiaoran , Wei, Zhishuo , Pikis, Stylianos , Mantziaris, Georgios , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Kersh, Charles R. , Lee, Cheng-chia, Niranjan, Ajay , Hadjipanayis, Constantinos G., Lunsford, L. Dade , Sheehan, Jason P. , Mantziaris, Georgios , Perlow, Haley K , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mallela, Arka N. , Mathieu, David , Palmer, Joshua D. , Elhamdani, Shahed, Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | November 11, 2023 | Volume: 140 | Issue: 5 | Pages: 1233-1242

10.3171/2023.8.jns231231 | PMID 37948682 Get It

OBJECTIVE The goal of this study was to characterize local tumor control (LC), overall survival (OS), and safety of stereotactic radiosurgery for colorectal brain metastasis (CRBM). METHODS Ten international institutions participating in the International Radiosurgery Research Foundation provided data for this retrospective case series. This study included 187 patients with CRBM (281 tumors), with a median age of 62 years and 56.7% being male. Most patients (53.5%) had solitary tumors, although 10.7% had > 5 tumors. The median tumor volume was 2.7 cm3 (IQR 0.22–8.1 cm3), and the median margin dose was 20 Gy (IQR 18–22 Gy). RESULTS The 3-year LC and OS rates were 72% and 20%, respectively. Symptomatic adverse radiation effects occurred in 1.6% of patients. In the multivariate analysis, age > 65 years and tumor volume > 4.0 cm3 were significant predictors of tumor progression (hazard ratio [HR] 2.6, 95% CI 1.4–4.9; p = 0.003 and HR 3.4, 95% CI 1.7–6.9; p < 0.001, respectively). Better performance status (Karnofsky Performance Scale score > 80) was associated with a reduced risk of tumor progression (HR 0.38, 95% CI 0.19–0.73; p = 0.004). Patient age > 62 years (HR 1.6, 95% CI 1.1–2.3; p = 0.03) and the presence of active extracranial disease (HR 1.7, 95% CI 1.1–2.4; p = 0.009) were significantly associated with worse OS. CONCLUSIONS Stereotactic radiosurgery offers a high LC rate and a low rate of symptomatic adverse radiation effects for the majority of CRBMs. The OS and LC favored younger patients with high functional performance scores and inactive extracranial disease.
From Consensus to Validation: A Multicenter Study for Design and Development of a Holmium Laser Enucleation of the Prostate Hydrogel Simulation Platform
Shepard, Lauren , Schuler, Nathan , Narang, Gopal , Humphreys, Mitchell R. , Krambeck, Amy E. , Humphreys, Mitchell, Setia, Shaan A. , Das, Akhil Kumar , Miller, Nicole L. , Ghazi, Ahmed

Mayo Clinic

Journal of Endourology | November 2, 2023 | Volume: 38 | Issue: 1 | Pages: 60-67

10.1089/end.2023.0430 | PMID 37917099 Get It

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Ahmed, Muneeb , Shepard, Dale R. , Bekaii‐Saab, Tanios , Wolff, Johannes Ernst Alexander

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: TPS3628-TPS3628

10.1200/jco.2023.41.16_suppl.tps3628 Get It

TPS3628 Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer-related mortality worldwide. PD-1/PD-L1 inhibition, in combination with other modalities, has demonstrated significant benefit in patients (pts) with microsatellite instability-high or mismatch repair deficient CRC. However, these agents have limited, if any, clinical benefit in pts with microsatellite stable (MSS) or mismatch repair proficient (pMMR) CRC. RP2 is an enhanced potency oncolytic herpes simplex virus type 1 which expresses the fusogenic gibbon ape leukemia virus glycoprotein with the R sequence deleted (GALV-GP-R–), granulocyte-macrophage colony-stimulating factor (GM-CSF), and an anti–CTLA-4 antibody-like molecule; RP3 additionally expresses 4-1BB and CD40 activating ligands, but does not express GM-CSF. Both agents have demonstrated preliminary safety and efficacy in pts with solid tumors. This study will evaluate the safety and efficacy of RP2 and RP3 in combination with atezolizumab (Atezo) and bevacizumab (Bev) in pts with advanced MSS and pMMR CRC. Methods: Pts with a histologic diagnosis of unresectable and/or metastatic CRC, with documented MSS or pMMR status, and previously treated with up to 3 standard-of-care systemic regimens will be enrolled in the RP2 + Atezo + Bev or RP3 + Atezo + Bev treatment groups (30 pts per group). Further key inclusion criteria include Eastern Cooperative Oncology Group performance status 0–1 and adequate hepatic, renal, and hematologic function. RP2/RP3 will be injected into tumors by direct (including via colonoscope) or image-guided injection. Pts will receive 8 total doses of up to 10 mL of RP2 or RP3, with a first dose concentration of 1 × 106 plaque-forming units (PFU)/mL, followed by 3 doses of 1 × 107 PFU/mL every 2 weeks, and then 4 doses of 1 × 107 PFU/mL every 3 weeks. Pts may receive a second course of up to 8 injections of RP2/RP3 if study criteria are met. Bev will be administered starting on day 1 (with first dose of RP2/RP3); Atezo will be administered starting week 7 on the same days as RP2/RP3. The primary endpoint is objective response rate; secondary endpoints are safety, overall survival, progression-free survival, duration of response, and complete response rate. Antitumor activity will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 as modified for this study. Safety will be assessed by physical examination, clinical laboratory evaluations, vital signs, and monitoring for adverse events (AEs; including serious AEs). Clinical trial information: NCT05733611 .
Local Control and Survival Outcomes After Stereotactic Radiosurgery for Brain Metastases From Gastrointestinal Primaries: An International Multicenter Analysis
Singh, Raj , Bowden, Greg , Mathieu, David , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Emad, Reem M. , Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Wei, Zhishuo , Legarreta, Aimé Parra , Hess, Judith, Templeton, Kelsey, Pikis, Stylianos , Mantziaris, Georgios , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Niranjan, Ajay , Kersh, Charles R. , Lee, Cheng‐Chia , Lunsford, L. Dade , Sheehan, Jason P. , Mathieu, David , Mantziaris, Georgios , Perlow, Haley K , Palmer, Joshua D. , Elhamdani, Shahed, Reda, Wael A. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | March 21, 2023 | Volume: 93 | Issue: 3 | Pages: 592-598

10.1227/neu.0000000000002456 | PMID 36942965 Get It

BACKGROUND: There are limited data regarding outcomes for patients with gastrointestinal (GI) primaries and brain metastases treated with stereotactic radiosurgery (SRS). OBJECTIVE: To examine clinical outcomes after SRS for patients with brain metastases from GI primaries and evaluate potential prognostic factors. METHODS: The International Radiosurgery Research Foundation centers were queried for patients with brain metastases from GI primaries managed with SRS. Primary outcomes were local control (LC) and overall survival (OS). Kaplan-Meier analysis was used for univariate analysis (UVA) of prognostic factors. Factors significant on UVA were evaluated with a Cox multivariate analysis proportional hazards model. Logistic regressions were used to examine correlations with RN. RESULTS: We identified 263 eligible patients with 543 brain metastases. Common primary sites were rectal (31.2%), colon (31.2%), and esophagus (25.5%) with a median age of 61.6 years (range: 37-91.4 years) and a median Karnofsky performance status (KPS) of 90% (range: 40%-100%). One-year and 2-year LC rates were 83.5% (95% CI: 78.9%-87.1%) and 73.0% (95% CI: 66.4%-78.5%), respectively. On UVA, age >65 years ( P = .001), dose <20 Gy ( P = .006) for single-fraction plans, KPS <90% ( P < .001), and planning target volume ≥2cc ( P = .007) were associated with inferior LC. All factors other than dose were significant on multivariate analysis ( P ≤ .002). One-year and 2-year OS rates were 68.0% (95% CI: 61.5%-73.6%) and 31.2% (95% CI: 24.6%-37.9%), respectively. Age > 65 years ( P = .006), KPS <90% ( P = .005), and extracranial metastases ( P = .05) were associated with inferior OS. CONCLUSION: SRS resulted in comparable LC with common primaries. Age and KPS were associated with both LC and OS with planning target volume and extracranial metastases correlating with LC and OS, respectively. These factors should be considered in GI cancer patient selection for SRS.
Effects of Neuroanatomic Structural Distances on Pituitary Function After Stereotactic Radiosurgery: A Multicenter Study
Ironside, Natasha , Xu, Zhiyuan , Schlesinger, David, Vance, Mary Lee, Hong, Gregory K. , Jane, John A. , Patel, Samir , Bindal, Shray K., Niranjan, Ajay , Lunsford, L. Dade , Chytka, Thomas, Berger, Assaf , Bernstein, Kenneth , Hernández, Wenceslao, Lazo, Erwin , Peker, Selçuk , Samancı, Yavuz , Mau, Christine, Wegner, Rodney E. , Shepard, Matthew J., Mathieu, David , Maillet, Michel, Sheehan, Jason P. , Mathieu, David , Chen, Ching‐Jen , Bindal, Shray Kumar, Liščák, Roman , Ježková, Jana , Saifi, Omran , Trifiletti, Daniel M. , Alzate, Juan, Kondziolka, Douglas , Speckter, Herwin , Zacharia, Brad E.

Mayo Clinic

Neurosurgery | January 26, 2023 | Volume: 92 | Issue: 5 | Pages: 1035-1042

10.1227/neu.0000000000002347 | PMID 36700741 Get It

BACKGROUND: Delayed hypopituitarism is the most common complication after stereotactic radiosurgery (SRS) for pituitary adenomas. OBJECTIVE: To investigate the relationship between neuroanatomic structure distances from the radiation target and anterior pituitary function preservation after SRS through multicenter study. METHODS: We retrospectively reviewed the International Radiosurgery Research Foundation database from January 2002 to December 2021 for adult patients undergoing SRS for pituitary adenomas with >6 months of follow-up. Distances between centers or edges of hypothalamic-pituitary axis structures and SRS target volumes were measured using MRI. The primary outcome was anterior pituitary function preservation. Predictors were analyzed using multivariable logistic regression and area under the receiver operating curve (AUROC) curve analyses. RESULTS: Four hundred eighty-seven patients were categorized by preservation (n = 384) and no preservation (n = 103) of anterior pituitary function. The mean margin dose was 19.1(6.2) Gy. Larger distance from the center of the stalk to the tumor margin isodose was a positive predictor (adjusted odds ratio [aOR] = 1.162 [1.046-1.291], P = .005), while pre-SRS hypopituitarism (aOR = 0.646 [0.405-1.031], P = .067) and larger treatment volume (aOR = 0.965 [0.929-1.002], P = .061) were near negative predictors of the primary outcome. An interaction between the treatment volume and center stalk to margin isodose distance was found (aOR = 0.980 [0.961-0.999], P = .045). Center stalk to margin isodose distance had an AUROC of 0.620 (0.557-0.693), at 3.95-mm distance. For patients with treatment volumes of <2.34 mL, center stalk to margin isodose distance had an AUROC of 0.719 (0.614-0.823), at 2.95-mm distance. CONCLUSION: Achieving a distance between the center of the pituitary stalk and the tumor margin isodose ≥3.95 mm predicted anterior pituitary function preservation. For smaller treatment volumes <2.34 mL, the optimal distance was ≥2.95 mm. This may be modifiable during trans-sphenoidal resection to preserve pituitary function.